- Home
- CANF vs ALCE Comparison
CANF vs ALCE Comparison
Compare CANF & ALCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ALCE
- Stock Information
- Founded
- CANF 1994
- ALCE 2019
- Country
- CANF Israel
- ALCE United States
- Employees
- CANF N/A
- ALCE N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ALCE Power Generation
- Sector
- CANF Health Care
- ALCE Utilities
- Exchange
- CANF Nasdaq
- ALCE Nasdaq
- Market Cap
- CANF 14.4M
- ALCE 3.7M
- IPO Year
- CANF N/A
- ALCE N/A
- Fundamental
- Price
- CANF $1.48
- ALCE $0.84
- Analyst Decision
- CANF Strong Buy
- ALCE
- Analyst Count
- CANF 2
- ALCE 0
- Target Price
- CANF $14.00
- ALCE N/A
- AVG Volume (30 Days)
- CANF 1.2M
- ALCE 99.3K
- Earning Date
- CANF 12-31-2024
- ALCE 11-19-2024
- Dividend Yield
- CANF N/A
- ALCE N/A
- EPS Growth
- CANF N/A
- ALCE N/A
- EPS
- CANF N/A
- ALCE N/A
- Revenue
- CANF $667,000.00
- ALCE N/A
- Revenue This Year
- CANF $409.56
- ALCE N/A
- Revenue Next Year
- CANF N/A
- ALCE N/A
- P/E Ratio
- CANF N/A
- ALCE N/A
- Revenue Growth
- CANF N/A
- ALCE N/A
- 52 Week Low
- CANF $1.29
- ALCE $0.74
- 52 Week High
- CANF $4.69
- ALCE $140.75
- Technical
- Relative Strength Index (RSI)
- CANF 35.58
- ALCE 28.33
- Support Level
- CANF $1.30
- ALCE $0.75
- Resistance Level
- CANF $1.72
- ALCE $0.84
- Average True Range (ATR)
- CANF 0.18
- ALCE 0.11
- MACD
- CANF -0.01
- ALCE 0.03
- Stochastic Oscillator
- CANF 17.92
- ALCE 19.04
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ALCE Alternus Clean Energy Inc.
Alternus Clean Energy Inc is an international independent clean energy producer. It develops, installs, owns and operates a diverse portfolio of utility-scale solar photovoltaic power stations (PV parks) in Europe and the USA as a long-term owner. The solar parks benefit from long-term government offtake contracts and/or Power Purchase Agreements (PPAs) with investment grade off-takers, plus energy sales to local power grids. It has approximately 8 operating parks, a total of 44 MWp in operation.